文献速递慢性肾脏病肾血管病与高血压

CONFIDENCE试验:在肾脏风险谱系中同时启用非奈利酮与恩格列净

Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial.
PubMed 文献 · Nephrol Dial Transplant · 2025-01-01

CONFIDENCE试验是一项双盲双模拟随机对照研究,纳入818例慢性肾脏病(CKD)合并2型糖尿病成人患者,比较非奈利酮联合恩格列净与两种单药治疗。预设分析显示,联合治疗在全部KDIGO风险类别中均显著降低尿白蛋白-肌酐比值(UACR),且降幅一致大于任一单药,安全性在各风险类别中保持一致。

要点

  • 联合治疗在180天时降低UACR:低/中危-61.7%、高危-60.7%、极高危-52.4%。
  • UACR降幅>30%的患者比例:低/中危58.1%、高危74.2%、极高危70.6%,均优于单药。
  • 高钾血症在联合治疗中更常见,但整体安全性在各KDIGO风险类别中一致。

核心结论

  • CONFIDENCE试验表明,同时启用非奈利酮与恩格列净联合治疗的相对疗效和安全性在广泛预测肾脏病风险谱系中保持一致。

研究设计与样本

  • 双盲、双模拟随机对照试验,纳入818例CKD合并2型糖尿病成人患者(UACR≥100至<5000 mg/g)。
  • 患者随机接受每日一次非奈利酮联合恩格列净、非奈利酮单药或恩格列净单药,均在肾素-血管紧张素系统抑制剂基础上加用。
  • 预设分析按KDIGO风险类别评估从基线至第180天UACR相对变化(主要终点)及UACR降低>30%(次要终点)。

主要发现

  • 基线时781例有数据者中,低/中危占11.3%、高危占29.6%、极高危占59.2%。
  • 第180天,联合治疗在所有KDIGO风险类别中显著降低UACR:低/中危-61.7%、高危-60.7%、极高危-52.4%。
  • 联合治疗UACR降幅在各风险类别中均一致大于任一单药治疗。
  • 联合治疗中超过半数患者UACR降低>30%:低/中危58.1%、高危74.2%、极高危70.6%,各风险组均优于单药。
  • 高钾血症在联合治疗中更常见,但早期eGFR下降(30天内>30%)在较高KDIGO风险者中较低风险者更不频繁。

关键数值与推荐

  • 联合治疗第180天UACR相对变化:低/中危-61.7%、高危-60.7%、极高危-52.4%。
  • 联合治疗UACR降低>30%的患者比例:低/中危58.1%、高危74.2%、极高危70.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The CONFIDENCE (COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with CKD and type 2 diabetes using a UACR Endpoint) trial investigated the safety and efficacy of simultaneously initiating finerenone and empagliflozin for patients with chronic kidney disease (CKD) and type 2 diabetes. This prespecified analysis aimed to determine if the predicted risk of kidney disease progression, based on KDIGO risk categories, influenced the benefits and safety of this combination therapy. METHODS: The double-blind, double-dummy trial randomized 818 adults with CKD and type 2 diabetes [urine albumin-creatinine ratio (UACR) ≥100 to <5000 mg/g] to receive once-daily finerenone plus empagliflozin, finerenone alone or empagliflozin alone, all in addition to a renin-angiotensin system inhibitor. The relative change in UACR from baseline to day 180 (primary endpoint) and a >30% reduction in UACR (secondary endpoint) across KDIGO risk categories was assessed. RESULTS: At baseline, among 781 with available data, 11.3% of participants were classified as low/moderate risk, 29.6% as high risk and 59.2% as very high risk. At 180 days, combination therapy significantly reduced UACR levels across all KDIGO risk categories (low/moderate: -61.7%; high: -60.7%; very high: -52.4%). This reduction was consistently greater than that achieved with either monotherapy alone. More than half of patients on combination therapy experienced UACR reductions of >30% (low/moderate: 58.1%; high: 74.2%; very high: 70.6%), again outperforming monotherapies across all risk groups. While hyperkalemia was more common with combination therapy, early eGFR declines (>30% within 30 days) were less frequent in individuals with higher KDIGO risk compared with lower risk. Overall, the safety profile of combination therapy remained consistent across all KDIGO risk categories, with no unexpected safety signals. CONCLUSIONS: The CONFIDENCE trial demonstrates that the relative efficacy and safety of simultaneous finerenone and empagliflozin combination therapy are consistent across a wide spectrum of predicted kidney disease risk. CLINICAL TRIAL REGISTRATION: NCT05254002; EudraCT 2021-003037-11.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Vaduganathan M, Green JB, Heerspink HJL, et al. Simultaneous initiation of finerenone and empagliflozin across the spectrum of kidney risk in the CONFIDENCE trial. Nephrol Dial Transplant. 2025. PMID: 40886054. doi:10.1093/ndt/gfaf160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。